Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Hunting H1 underlying earnings up 16pc, proposes $40m share buyback

(Sharecast News) - Oil and gas industry supplier Hunting said on Tuesday that it had delivered good year-on-year underlying earnings growth in H125, leading the group to propose a $40.0m share buyback. Hunting said underlying earnings were up roughly 16% in H1 at $68.0m to $70.0m, led by a "robust contribution" from its OCTG product group, while EBITDA margins came to approximately 13% in the period.

The FTSE 250-listed firm said its period-end sales order book was around $450.0m, ahead of its Q125 position of $439.0m, with a tender pipeline of approximately $1.1bn.

Hunting also said it had secured $38.0m of new orders for its titanium stress joints in the Gulf of Mexico, as well as new plug and abandonment and field decommissioning projects in the North Sea.

Looking forward, Hunting's targeted annual dividend increase was raised from 10% to 13%, while FY EBITDA guidance of $135.0m to $145.0m was retained.

Hunting also said a share buyback programme of up to $40.0m was scheduled to commence following publication of its interim results, with the intention of being completed over the next 12 months.

As of 0840 BST, Hunting shares were up 13.98% at 342.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.